Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis

医学 内科学 免疫疗法 胃肠病学 荟萃分析 结果(博弈论) 肿瘤科 癌症 数理经济学 数学
作者
Ismael El Hajra,Marco Sanduzzi‐Zamparelli,Víctor Sapena,Sergio Muñoz,Ezequiel Mauro,Neus Llarch,Gemma Iserte,Alejandro Forner,José Ríos,Jordi Bruix,María Reig
出处
期刊:Hepatology [Lippincott Williams & Wilkins]
卷期号:77 (4): 1139-1149 被引量:21
标识
DOI:10.1097/hep.0000000000000030
摘要

Background and Aims: Immunotherapy-based regimes have changed the management of HCC. However, evidence of efficacy in patients with impaired liver function is unknown. This systematic review and meta-analysis assesses survival of HCC patients and liver dysfunction treated with immunotherapy-based regimens. Methods: Systematic review and meta-analysis of original articles or abstracts reporting survival of HCC patients treated with immunotherapy according to liver function between 2017 and 2022. Overal survival (OS) according to restricted mean survival time (RMST) and median OS, and hazard ratio (HR) of Child-Pugh B or B/C versus Child-Pugh A were assessed while considering the line of treatment. Results: Of the 2218 articles considered, 15 articles recruiting 2311 patients were included. Of these, 639 (27.7%) were Child-Pugh B and 34 (1.5%) C. RMST was 8.36 (95% CI, 6.15–10.57; I 2 =93%) months, estimated from 8 studies. The HR was reported in 8 studies for survival between Child-Pugh B versus Child-Pugh A and metanalysis disclosed a 1.65 HR (95% CI,1.45–1.84; I 2 =0% heterogeneity; p = 0.45). Treatment line data were available for 47% of the patients and 3 studies included patients treated with atezolizumab-bevacizumab in the first line. Conclusions: The high heterogeneity across studies reflects the incapacity of the current evidence to support the indication of immunotherapy in HCC patients with relevant liver dysfunction. It is mandatory to report complementary information to Child-Pugh classification such as prior liver decompensation, use of concomitant medication to control ascites, or signs of clinically significant portal hypertension to allow better patient stratification in future studies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
淳于安筠完成签到,获得积分10
刚刚
雨晴完成签到,获得积分10
3秒前
jbq发布了新的文献求助10
3秒前
joshar完成签到,获得积分10
3秒前
4秒前
量子星尘发布了新的文献求助10
6秒前
blueblue完成签到,获得积分10
8秒前
落后秋烟完成签到,获得积分10
10秒前
大橙子发布了新的文献求助10
11秒前
LMY完成签到 ,获得积分10
11秒前
Betty完成签到 ,获得积分10
11秒前
NexusExplorer应助jbq采纳,获得10
12秒前
渔渔完成签到 ,获得积分10
12秒前
13秒前
Tangyartie完成签到 ,获得积分10
13秒前
skbkbe完成签到 ,获得积分10
14秒前
陈俊雷完成签到 ,获得积分0
15秒前
阿苗完成签到,获得积分10
16秒前
神勇的天问完成签到 ,获得积分10
17秒前
17秒前
advance完成签到,获得积分10
17秒前
李cc发布了新的文献求助10
18秒前
蒋念寒发布了新的文献求助10
19秒前
Sindy完成签到,获得积分10
19秒前
彭于晏应助HH采纳,获得30
21秒前
21秒前
朴实的小萱完成签到 ,获得积分10
22秒前
科研通AI5应助哭泣笑柳采纳,获得10
22秒前
22秒前
温暖的蚂蚁完成签到 ,获得积分10
25秒前
dhn123完成签到,获得积分10
25秒前
ccx完成签到,获得积分10
25秒前
26秒前
biofresh发布了新的文献求助30
26秒前
科研顺利完成签到,获得积分10
27秒前
Owen应助科研通管家采纳,获得10
28秒前
JamesPei应助科研通管家采纳,获得10
28秒前
NexusExplorer应助科研通管家采纳,获得30
29秒前
Nick应助科研通管家采纳,获得10
29秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022